It's been a pretty great week for Medistim ASA (OB:MEDI) shareholders, with its shares surging 18% to kr284 in the week since its latest quarterly results. Medistim beat revenue forecasts by a solid 11% to hit kr167m. Statutory earnings per share came in at kr5.67, in line with expectations. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
Following the latest results, Medistim's twin analysts are now forecasting revenues of kr753.5m in 2026. This would be a notable 14% improvement in revenue compared to the last 12 months. Per-share earnings are expected to ascend 17% to kr9.14. Yet prior to the latest earnings, the analysts had been anticipated revenues of kr715.0m and earnings per share (EPS) of kr8.48 in 2026. It looks like there's been a modest increase in sentiment following the latest results, withthe analysts becoming a bit more optimistic in their predictions for both revenues and earnings.
View our latest analysis for Medistim
With these upgrades, we're not surprised to see that the analysts have lifted their price target 8.6% to kr315per share.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Medistim's past performance and to peers in the same industry. The period to the end of 2026 brings more of the same, according to the analysts, with revenue forecast to display 11% growth on an annualised basis. That is in line with its 12% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 6.9% annually. So it's pretty clear that Medistim is forecast to grow substantially faster than its industry.
The Bottom Line
The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Medistim following these results. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have analyst estimates for Medistim going out as far as 2027, and you can see them free on our platform here.
However, before you get too enthused, we've discovered 1 warning sign for Medistim that you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Medistim might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.